Moreover, in preclinical experiments the effect of treatment with recombinant IL-22 [88], anti-IL-20, or anti-IL-20RA monoclonal antibody [77] was demonstrated to inhibit TGF-β production or the excessive accumulation of ECM components in mouse models of liver fibrosis induced by chemical agents (CCl4) or mechanical bile duct ligation. The gene discussed is IL22; the disease is Hepatic fibrosis.